[1] | Skvortsova I, Skvortsov S, Haidenberger A, Devries A, Nevinny-Stickel M, Saurer M, Lukas P, Seppi T. Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J Chemother. 2004 Aug;16(4):372-80. |
[2] | Skvortsov S, Sarg B, Loeffler-Ragg J, Skvortsova I, Lindner H, Werner Ott H, Lukas P, Illmensee K, Zwierzina H. Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Mol Cancer Ther. 2004 Dec;3(12):1551-8. |
[3] | Skvortsova I, Popper BA, Skvortsov S, Saurer M, Auer T, Moser R, Kamleitner H, Zwierzina H, Lukas P. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.J Radiat Res (Tokyo). 2005 Jun;46(2):241-8. |
[4] | Loeffler-Ragg J, Skvortsov S, Sarg B, Skvortsova I, Witsch-Baumgartner M, Mueller D, Lindner H, Zwierzina H. Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. Eur J Cancer. 2005 Oct;41(15):2338-46. |
[5] | Skvortsov S, Skvortsova I, Sarg B, Loeffler-Ragg J, Lindner H, Lukas P, Tabernero J, Zwierzina H. Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. Apoptosis. 2005 Oct;10(5):1175-86. |
[6] | Skvortsova I, Skvortsov S, Popper BA, Haidenberger A, Saurer M, Gunkel AR, Zwierzina H, Lukas P. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and-independent mechanisms. J Radiat Res (Tokyo). 2006 Jun;47(2):183-96. |
[7] | von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C. (99m)Tc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1209-18. |
[8] | Skvortsov S, Skvortsova I, Stasyk T, Schiefermeier N, Neher A, Gunkel AR, Bonn GK, Huber LA, Lukas P, Pleiman CM, Zwierzina H. Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines. Mol Cancer Ther. 2007 Jun;6(6):1898-908. |
[9] | Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, Pervin A, Tseng B, Carlson RO, Pleiman CM. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71. |
[10] | Skvortsov S, Sarg B, Lindner H, Lukas P, Hilbe W, Zwierzina H, Skvortsova I. Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. Proteomics Clin Appl. 2008, 2, 908-914. |
[11] | Skvortsova I, Skvortsov S, Stasyk S, Raju U, Popper B-A, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA, Lukas P. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics, 2008 Nov;8(21):4521-33. |
[12] | Skvortsova I. Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab. Radiother Oncol. 2009 Febr;90:280–283. |
[13] | Loeffler-Ragg J, Mueller D, Gamerith G, Auer T, Skvortsov S, Sarg B, Skvortsova I, Schmitz KJ, Martin HJ, Krugmann J, Alakus H, Maser E, Menzel J, Hilbe W, Lindner H, Schmid KW, Zwierzina H. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol Cancer Ther. 2009 Jul;8(7):1995-2006. |
[14] | Skvortsova I, Skvortsov S, Raju U, Stasyk T, Riesterer O, Schottdorf EM, Popper BA, Schiestl B, Eichberger P, Debbage P, Neher A, Bonn GK, Huber LA, Milas L, Lukas P. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiother Oncol. 2010 July; 96: 108–115. |
[15] | Haidenberger A., Fromm-Haidenberger S., de Vries A., Popper B.A., Steurer M., Skvortsova I., Kantner J., Gunsilius E., Lukas P. Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab(®)) for Patients with Non-Hodkin's Lymphoma : Results of a Prospective Phase I/II Study. Strahlenther Onkol. 2011 May;187(5):300-305. Epub 2011 Apr 26. |
[16] | Skvortsov S., Jimenez C.R., Knol J.C., Eichberger P., Schiestl B., Debbage P., Skvortsova I., Lukas P. Radioresistant head and neck squamous cell carcinoma cells: intracellular signalling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiother Oncol. 2011 (in press). |
[17] | Skvortsova I, Pustoshilova N. Rectal Carcinoma Yields to Immuno/Chemo Technique. Oncology News, November-December, 21 (6): 3-5; 1995. |
[18] | Skvortsova I, Popper B-A, Seppi T, Lukas P. FLT3-ligand administration for the generation of immune response in BALB/c mice during irradiation. Progress in Radio-Oncology VII, Proceedings, 2001: 647-651. |
[19] | Schottdorf EM, Skvortsov S, Huber LA, Stasyk T, Lukas P, Skvortsova I. Therapieantwort auf kombinierte Radioimmuntherapie mit Cetuximab. OeGRO-Jahrestagung: Kopf-Hals-Tumoren, Hämatologie & Onkologie 1/2011. |